Ionis Pharmaceuticals (IONS) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Ionis Pharmaceuticals (IONS) over the past year, gaining 351.9% versus a loss of 38.1%. Over five years, IONS leads with a +23.4% price change compared with -60.9% for SYRE. Spyre Therapeutics is the larger company by market cap ($7.91 billion vs $7.52 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IONS | SYRE |
|---|---|---|
| Share price | $45.28 | $85.69 |
| Market cap | $7.52B | $7.91B |
| 1-day change | +4.57% | +7.25% |
| YTD return | -45.27% | +143.89% |
| 1-year return | -38.11% | +351.92% |
| 5-year return | +23.36% | -60.93% |
| EPS (TTM) | $-3.48 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $943.71M | $0 |
| Revenue growth (YoY) | +33.83% | — |
| Net income (latest FY) | $-381.39M | $-155.20M |
| Gross margin | 98.31% | — |
| Operating margin | -40.45% | — |
| Net margin | -40.41% | — |
| 52-week high | $86.74 | $110.18 |
| 52-week low | $42.63 | $18.12 |
| Distance from 52-week high | -47.80% | -22.22% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +84.72% | +40.28% |
| Average volume | 3.51M | 1.22M |
| Shares outstanding | 166.18M | 92.29M |
| Employees | 1,480 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed IONS by 390.0 percentage points over the past year.
About Ionis Pharmaceuticals
IONS stock →Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA).
Health Care · Biotechnology: Pharmaceutical Preparations · 1,480 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
IONS vs SYRE FAQ
Which is bigger, Ionis Pharmaceuticals or Spyre Therapeutics?
Spyre Therapeutics (SYRE) is larger, with a market capitalization of $7.91B compared with $7.52B for Ionis Pharmaceuticals (IONS).
Which stock has performed better over the past year, IONS or SYRE?
SYRE returned +351.92% over the past 12 months, compared with -38.11% for IONS (price return, excluding dividends). Past performance does not predict future results.
Are Ionis Pharmaceuticals and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.